NPM-ALK signals through glycogen synthase kinase 3Β to promote oncogenesis

Oncogene

Volumn 31, Issue 32, 2012, Pages 3733-3740

  McDonnell, S R P ^a   Hwang, S R ^a   Basrur, V ^a   Conlon, K P ^a   Fermin, D ^a   Wey, E ^a   Murga Zamalloa, C ^a   Zeng, Z ^b   Zu, Y ^b   Elenitoba Johnson, K S J ^a   Lim, M S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

ALCL; GSK3; NPM ALK; oncogenesis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYBRID PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84864949954     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.542     Document Type: Article

References (32)

1. Amin HM, Lai R. (2007). Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110: 2259-2267.
2. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. (1998). Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 6951-6961.
3. Bischof D, Pulford K, Mason DY, Morris SW. (1997). Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphomaassociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325.
4. Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L et al. (2009). The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113: 2776-2790.
5. Bostock CJ, Prescott DM, Kirkpatrick JB. (1971). An evaluation of the double thymidine block for synchronizing mammalian cells at the G1-S border. Exp Cell Res 68: 163-168.
6. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S et al. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940.
7. Cohen P, Frame S. (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
9. Diehl JA, Zindy F, Sherr CJ. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972.
10. Fernandez-Vidal A, Mazars A, Gautier EF, Prevost G, Payrastre B, Manenti S. (2009). Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle 8: 1373-1379.
11. Frame S, Cohen P, Biondi RM. (2001). A common phosphate-binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327.
12. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. (2010). Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116: 2078-2088.
13. Ito M, Zhao N, Zeng Z, Chang CC, Zu Y. (2010). Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Cancer Gene Ther 17: 633-644.
14. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439-449.
15. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H et al. (1994). Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13: 1549-1556.
16. Jope RS, Johnson GV. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
17. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC et al. (2008). GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13: 36-47.
18. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. (2011). CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-594.
19. Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF et al. (2009). The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood 114: 1585-1595.
20. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. (2006). Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26: 813-821.
21. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
22. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M et al. (2003). GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1255-1266.
23. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
24. Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV. (2010). Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett 1: 493-498.
25. Palmer RH, Vernersson E, Grabbe C, Hallberg B. (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361.
26. Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C. (2003). Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol 31: 309-315.
27. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ et al. (2005). Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94-101.
28. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L et al. (2001). Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61: 2194-2199.
29. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. (2002). Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem 277: 17901-17905.
30. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51.
31. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. (2002). Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21: 1038-1047.
32. Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL et al. (2007). Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 27: 4328-4339.